A network pharmacological study of convalescent COVID-19 prescription (CCP) on SARS-COV-2 infection-related pulmonary fibrosis showed that CCP could inhibit the expression of VEGF, TNF-α, IL-6, MMP9, and TGF-β1 through VEGF, Toll-like four receptor, MAPK, and TGF-β1 signaling pathways, which may be the reason why the CCP works as an anti-fibrotic (Jin et al., 2021). Here, TGFB1 is linked to COVID-19.